Saturday 7 November 2026 Export TNXP’s income statement to Excel — free account

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024.

Revenue: +577.9%
EPS: +36.8%
Free cash flow: −178.8%

Quarter to June 2026, against a year earlier

Insider buying

4.77 0.17 +3.70%

Follow TNXP

Alert me

Market cap: $78.9M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 5/9
Altman Z: −2.42
Beneish M: −2.38
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.46

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	2	—	—	3	—	2	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 78.89

Revenue ttm 29.10

Net income ttm (159.67)

Free cash flow ttm (158.11)

Net debt Q (176.23)

Valuation

P/E 0.00

Forward P/E (0.52)

Price / sales 2.73

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.36

Financial health

Current ratio Q 6.61

Debt / equity Q 0.00

Interest coverage Q (24.09)

Growth

Revenue growth Q +577.88%

Operating income growth Q −50.32%

EPS, this year +32.89%

EPS, next year A +34.41%

Revenue, next year A +325.42%

EPS, past 5 yrs —

EPS, next 5 yrs A +36.41%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 27.02%

10-year low 10-year high

EV/FCF against its own 10 years 54.03%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	25	99	208	176
Receivables	—	4	6	12
Inventory	14	8	6	5
Other	—	—	—	—
	48	119	229	203

	2023	2024	2025	Q'26
Payables	4	5	8	9
ST’ Debt	2	3	—	—
Other	—	—	—	—
	19	18	31	31

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	19.80%	22.84%	5.77%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −2.71 Actual −2.44

−4.22 −3.70 −3.18 −2.66 −2.14

Q3 FY25 Met 0.00

Q4 FY25 Miss −0.82

Q1 FY26 Miss −0.55

Q2 FY26 Beat +0.27

Q3 FY26 — Nov 9

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−3.59	−3.59	Met by 0.00
Q4 FY25	−3.16	−3.98	Miss by 0.82
Q1 FY26	−2.38	−2.93	Miss by 0.55
Q2 FY26	−2.71	−2.44	Beat by 0.27
Q3 FY26	−2.51	—	Reports 9 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.93)	(2.44)	—	—	—
’25	(2.84)	(3.86)	(3.59)	(3.95)	(14.57)
’24	(575.08)	(1.93k)	(23.00)	(9.77)	(176.60)
’23	(10.38k)	(4.92k)	(3.86k)	(1.76k)	(14.72k)
’22	(31.90k)	(24.36k)	(13.78k)	(11.18k)	(65.30k)
’21	(0.07)	(44.66k)	(31.90k)	(44.66k)	(165.87k)
’20	(236.04k)	(0.23)	(0.09)	(63.80k)	(0.53)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	14	—	—	—
’25	2	2	3	5	13
’24	2	2	3	3	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(42)	—	—	—
’25	(17)	(15)	(29)	(40)	(100)
’24	(18)	(10)	(19)	(15)	(61)
’23	(33)	(23)	(23)	(22)	(102)
’22	(31)	(21)	(24)	(22)	(98)
’21	(21)	(19)	(13)	(22)	(76)
’20	(9)	(10)	(15)	(14)	(49)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(43)	—	—	—
’25	(17)	(15)	(30)	(42)	(103)
’24	(18)	(10)	(19)	(15)	(61)
’23	(37)	(25)	(24)	(23)	(109)
’22	(51)	(36)	(32)	(27)	(146)
’21	(22)	(21)	(21)	(48)	(111)
’20	(9)	(10)	(19)	(18)	(57)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	8	10	13	29		+29.9%	56	111	183	+140.6%
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.97	23.07	49.34	83.83		+49.3 pt	Powerpack Tonix Pharmaceuticals Holding Corp.’s next three years, line by line Analysts expect revenue to grow 140.6% a year to 2028 — faster than the 29.9% of the last 2 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(39)	(21)	(26)	(29)	(50)	(92)	(110)	(117)	(130)	(124)	(160)		+13.8%
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(1,501.78)	(1,288.25)	(946.22)	(548.64)		(946.2) pt
	Net income	(39)	(21)	(26)	(29)	(50)	(92)	(110)	(117)	(130)	(124)	(160)		+13.8%
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	983.29	13.71	1.54	1.75		n/m
	Earnings	(15.41)	(31.67)	(259.85)	(17.79)	(0.53)	(165,868.80)	(65,295.53)	(14,720.25)	(176.60)	(14.57)	(12.91)		(0.6%)
	Cash flow	(14.80)	(28.68)	(212.13)	(16.58)	(0.51)	(125,928.33)	(54,473.89)	(12,911.77)	(82.74)	(11.73)	(9.20)		(2.5%)
	Capex	(0.03)	(0.01)	(0.05)	(0.01)	(0.09)	(58,845.00)	(26,748.33)	(872.91)	(0.16)	(0.40)	(0.31)		+35.2%
	Free cash flow	(14.83)	(28.69)	(212.19)	(16.59)	(0.60)	(184,773.33)	(81,222.22)	(13,784.68)	(82.91)	(12.13)	(9.50)		(2.2%)
	Book value	10.06	36.91	209.42	5.85	0.93	364,528.33	115,101.11	13,357.59	189.54	28.80	13.36		+12.4%
	Shares, m	3	1	0	2	95	0	0	0	1	9	12		+14.5%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	—	—	0.00	2.41	10.14	2.73		4.2
	P/B	—	—	—	—	—	—	—	0.20	0.17	0.54	0.36		0.3
	EV/Sales	—	—	—	—	—	—	—	0.00	(6.64)	(5.13)	(3.07)		(3.9)
	EV/FCF	—	—	—	—	—	—	—	(0.04)	1.10	0.65	0.57		0.6
Cash, $m
Cash, $m	Operating cash flow	(37)	(19)	(24)	(27)	(49)	(76)	(98)	(102)	(61)	(100)	(153)		+11.6%
	Capex	0	0	0	0	(9)	(35)	(48)	(7)	0	(3)	(5)		+54.8%
	Free cash flow	(37)	(19)	(24)	(27)	(57)	(111)	(146)	(109)	(61)	(103)	(158)		+11.9%
Balance, $m
Balance, $m	Working capital	25	24	23	9	78	167	113	29	101	198	173		+25.8%
	Net debt	(26)	(25)	(25)	(11)	(76)	(178)	(119)	(16)	(91)	(208)	(176)		+25.9%
	Shareholders’ equity	25	25	24	9	88	219	207	106	140	245	222		+28.7%
Returns, %
Returns, %	ROA	(104.23)	(77.85)	(110.62)	(152.12)	(92.56)	(54.43)	(50.10)	(61.38)	(81.95)	(56.37)	(72.34)		+47.9 pt
	ROIC	0.00	0.00	0.00	0.00	(265.49)	(140.67)	(79.87)	(82.68)	(177.00)	(209.43)	(224.52)		(209.4) pt
	ROE	(118.38)	(84.53)	(121.60)	(187.97)	(107.50)	(60.25)	(54.88)	(74.61)	(106.12)	(64.48)	(81.82)		+53.9 pt
People
People	Employees	18	14	12	16	26	73	117	76	57	142	—		+25.8%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.18	0.09	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RLYB Rallybio Corporation	$84.5M	3.3×	— (loss-making)	0.00%	n/m	+65.25% (above 0%: growing)	100.00%	0.00%	Compare
EQ Equillium, Inc.	$84.3M	— (loss-making)	— (loss-making)	−52.32% (below 0%: shrinking)	n/m	−38.67% (below 0%: shrinking)	100.00%	0.00%	Compare
GNLX Genelux Corporation	$82.4M	— (loss-making)	— (loss-making)	—	n/m	−11.18% (below 0%: shrinking)	100.00%	0.00%	Compare
KZIA Novogen Limited	$80.0M	— (loss-making)	— (loss-making)	—	−32.67% (below 0%: shrinking)	−51.71% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$79.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
TLSA Tiziana Life Sciences Ltd	$79.6M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—	Compare
TNXP Tonix Pharmaceuticals Holding Corp.	$78.9M	— (loss-making)	— (loss-making)	+577.88% (above 0%: growing)	n/m	−178.84% (below 0%: shrinking)	94.81%	(314.05%)
NRXS Neuraxis, Inc.	$76.7M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
CLLS Cellectis S.A.	$74.5M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
Median of peers	$80.0M	—	—	−52.32%	—	+3.42%	92.94%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 March 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	2.92m	4.59m	0.01
2024	1.81m	1.06m	0.01
2023	2.05m	647.04k	0.56

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Tonix Pharmaceuticals Holding Corp. (TNXP) Latest News

27 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

26 Oct

Impact 3 · 7:00 AM · GlobeNewswire earnings

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

22 Oct

Impact 3 · 6:00 AM · 24/7 Wall St.

A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays

19 Oct

Impact 3 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

15 Oct

Impact 3 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

22 Sep

Impact 4 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

11 Sep

Impact 4 · 10:01 PM · MarketBeat

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

2 Sep

Impact 3 · 9:38 AM

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

18 Aug

Impact 4 · 3:01 AM · MarketBeat

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

17 Aug

Impact 3 · 10:44 AM · The Motley Fool transcript

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

10 Aug

Impact 4 · 5:01 PM transcript

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

Impact 3 · 12:04 PM · MarketBeat transcript

Tonix Pharmaceuticals Q2 Earnings Call Highlights

3 Aug

Impact 4 · 7:00 AM

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

13 Jul

Impact 4 · 7:00 AM

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Impact 3 · 8:21 AM · InvestorsHub

Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)

29 Jun

Impact 3 · 7:25 AM

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

8 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Impact 3 · 9:46 AM · Stocktwits

Why Is TNXP Stock Rising Today?

20 May

Impact 4 · 10:25 AM · Zacks Small Cap Research

TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients

11 May

Impact 3 · 4:30 PM · GlobeNewswire

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

6 May

Impact 4 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

29 Apr

Impact 4 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

15 Apr

Impact 3 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

31 Mar

Impact 3 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

26 Mar

Impact 3 · 7:00 AM · GlobeNewswire

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

23 Mar

Impact 4 · 7:33 AM · Zacks Small Cap Research

TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch

12 Mar

Impact 4 · 5:30 PM

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

10 Mar

Impact 3 · 8:00 AM · GlobeNewswire

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

9 Mar

Impact 3 · 4:30 PM · GlobeNewswire

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Impact 3 · 4:30 PM · GlobeNewswire

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Tonix Pharmaceuticals Holding Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 March 2026

Chief executive’s pay

Tonix Pharmaceuticals Holding Corp. (TNXP) Latest News

27 Oct

26 Oct

22 Oct

19 Oct

15 Oct

22 Sep

11 Sep

2 Sep

18 Aug

17 Aug

10 Aug

3 Aug

13 Jul

29 Jun

8 Jun

20 May

11 May

6 May

29 Apr

15 Apr

31 Mar

26 Mar

23 Mar

12 Mar

10 Mar

9 Mar

Stockrow Weekly